Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.
about
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationGraft-versus-host disease biomarkers: omics and personalized medicineAdvances in predicting acute GVHDAcute graft-versus-host disease: a bench-to-bedside update.Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISAElafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Graft-versus-host disease: state of the science.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.Recent advances in the management of graft-versus-host disease.Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantationA diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre studyA refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationA donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantationImmune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantationInterleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease.Discovery and validation of graft-versus-host disease biomarkersCyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathPentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.Pathophysiology of GvHD and Other HSCT-Related Major Complications.Expression of Serum microRNAs is Altered During Acute Graft-versus-Host Disease.Assessing response of therapy for acute and chronic graft-versus-host disease.The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Advances in hematopoietic stem cell transplantation for primary immunodeficiency.Adult adherent stromal cells in the management of graft-versus-host disease.
P2860
Q26740251-C8CA5A55-CE4F-43C3-AC0B-458148E84E9BQ26824540-54DBE5EA-1814-4731-9BBC-67C16F40233BQ27021123-8D2092CD-C4F0-4D10-89F2-C8A2F7FA3469Q27687130-792AFE51-562B-4259-BB64-836EFF152705Q33554539-B25E9AA6-AC9A-44D4-A94C-C423C1C1FBAFQ33955266-6FDFB695-E4D4-4C7A-864C-EC5D0BA1CDE1Q33977923-8A57F72F-7834-4449-AFC8-E5C54377F943Q34093615-66BEAFB0-9D90-4AEE-858E-EB9FECD78B1AQ34325048-58015DF6-8F58-4E9E-9635-CF3881C432CBQ34428890-789F8AC0-A0C1-4299-B403-8AF8EA1C4DCCQ34551192-B78E1206-C6EB-44C2-9E4F-D9C4591C5F3FQ34626032-68D9ADDE-F8CF-4FBB-B8DF-2B1E632AD0C9Q34732865-1FF89C7E-7F55-4C4D-93F0-8CF0327AF480Q34802425-A05C5F1A-23A7-41FE-96F7-C56B3A9EA03EQ35120338-38D46F49-B573-4B76-AEF0-0EE78A308E9FQ35177453-B6BA0041-BD30-4478-A42A-ED0E9F8C8604Q35180727-BF64CE6E-1F53-4469-9C8F-4AE91E93D8A8Q35586614-8D7017FC-15E4-474B-ACCB-20FC315130DDQ36376817-ED34C3D6-4C23-4EC6-B748-2E1DE56DA4BEQ36434639-BA861111-9BB6-45A0-B321-75667C56436FQ36498345-6B80B0B2-7260-4B7B-80B6-FFE91FA84DEAQ36569667-2E61C0D8-54DD-4845-9D09-1B94AD5A1FBDQ36715943-9AE42F2C-0F3B-49E3-A53C-E051218F192EQ36777485-22254858-1BBB-43E4-BC5B-0024ECACE4E2Q36861714-D8BE5BF7-76F4-42D1-B282-46A4C0910017Q36905580-AA927E1A-164A-41A7-A15E-A5F5BEF62197Q36928351-A37ECDA1-BD6C-486D-B6C5-FBD237737891Q37402799-3939759F-9A6B-4CF4-BE90-6AF6B96A6176Q37535273-3E3D0D5C-31DC-45C4-B79C-69868D77DC0AQ37585022-AA51D98C-FC71-45BF-AC64-F2D96524BDFCQ37587724-BFBF7AF1-C997-46EB-954C-790A6E178784Q37618997-42EC7FCC-42D1-4436-AF1D-AD19075D8EBBQ37696092-C637CD74-7A9C-44D9-8062-68872CE654B5Q37710227-A2F76594-6A19-48AF-B2E8-362BB1187C6AQ37710572-2C9F167E-604F-46CF-B4CB-2CA7644A267EQ37718993-B80BE3D0-975D-4363-965A-EF64ACE30152Q38078431-D991DEAA-4FC8-4525-9A52-333183E138B9Q38083604-55C3090B-3BE2-4967-904E-AAC9FC84CA6CQ38152824-0C0C5319-EF29-440A-9BE0-1B66F2A7B7BCQ38176442-8DBC6383-791E-444B-ABEC-B43F0B0D2CFD
P2860
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@ast
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@en
type
label
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@ast
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@en
prefLabel
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@ast
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@en
P2093
P2860
P1433
P1476
Acute graft-versus-host diseas ...... Clinical Trials Network study.
@en
P2093
Amin M Alousi
Brent R Logan
Daniel J Weisdorf
James L M Ferrara
Javier Bolaños-Meade
John E Levine
Vincent T Ho
P2860
P304
P356
10.1182/BLOOD-2012-01-403063
P407
P577
2012-03-01T00:00:00Z